Health & Biotech Copy RSS link Link copied to clipboard!
Eli Lilly reports strong growth potential amidst regulatory challenges in 10-Q filing
On May 01, 2026, Eli Lilly and Co released its 10-Q filing for the quarter ending March 31, 2026. Revenue increased driven by higher volumes of cardiometabolic products Mounjaro and Zepbound, which accounted for 65% of total revenue. The company received FDA Breakthrough Therapy designation for sofetabart mipitecan for ovarian cancer. While the GF Score is 95/100 indicating strong potential, the company faces regulatory litigation regarding the 340B program and pricing pressures. The stock trades at $934.60, undervalued by 28.3% relative to a GF Value of $1302.77.
4DMedical announces collaboration with GlaxoSmithKline
4DMedical has announced a new agreement with GlaxoSmithKline to deliver lung imaging analytics for pulmonary drug development and clinical research. The collaboration integrates with an established research data platform to provide advanced imaging biomarkers for assessing lung function. This partnership builds on an existing relationship with AstraZeneca, reinforcing the company's footprint in the pharmaceutical sector. The deal highlights growing interest in data-driven respiratory diagnostics and non-invasive lung scanning technology, despite recent share price volatility.
Sun Pharma acquires Organon for $11.75 billion amid biopharma M&A surge
On 27 April 2026, Sun Pharma announced an all-cash acquisition of Organon valued at $11.75 billion. The deal includes 70 products in women's health and general medicines, including biosimilars. This transaction occurs as the global biopharmaceutical industry faces a significant revenue decline due to the Patent Cliff, with over $200 billion in annual revenue at risk of loss of exclusivity in the US by the end of the decade. The acquisition aims to secure an established portfolio and bypass the R&D cycle.
GLP-1 agonists classified as biological medicines in EU and UK
GLP-1 receptor agonists are peptide-based medicines regulated as biological medicines in the EU, UK, and most ICH-aligned jurisdictions. In the US, the FDA classifies most as drugs under the Federal Food, Drug, and Cosmetic Act unless they meet statutory biological definitions. Injectable products with integral delivery devices are regulated as combination drug-device products. Manufacturers must verify jurisdiction-specific classifications before filing strategies to avoid delays.
UK mental health nurses describe workload as unmanageable amid patient harm risks
A Royal College of Nursing (RCN) survey reveals that specialist mental health nurses in the UK consider their workload unmanageable, with only one in five reporting manageable caseloads. The poll indicates that 51% of respondents believe patients are frequently harmed due to high caseloads and understaffing. Demand for community services rose by 38% between 2022 and 2025, while the nursing workforce grew by just 15%. The RCN calls for urgent investment, while the Department of Health and Social Care cites record funding and recruitment increases.
Researchers present rapid multiplex molecular diagnostic systems at ESCMID conference
Global researchers presented preliminary data on new rapid molecular test systems at the European Society of Clinical Microbiology and Infectious Diseases annual conference in New York. Companies including Cepheid, SD Biosensor, Qiagen, and Diasorin showcased assays for pathogen identification and antimicrobial resistance. Presentations highlighted real-world data on workflow efficiency, cost savings, and improved diagnostic yield for conditions like meningitis and respiratory infections. Novel chemistries using CRISPR and thermal-induced switching probes were also demonstrated as potential future developments for faster, cheaper testing.
FDA and CMS announce RAPID coverage pathway for limited subset of medical devices
On April 23, 2026, the FDA and CMS announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) Coverage Pathway. While aimed at accelerating coverage for breakthrough devices, eligibility is restricted to Class II devices in the Total Product Life Cycle Advisory Program or Class III devices requiring Investigational Device Exemption studies. Estimates suggest only 40 to 60 devices qualify, leaving approximately 1,000 Breakthrough Devices without accelerated coverage. CMS will issue a proposed notice for a 60-day public comment period.
Antibiotic resistance market projected to reach USD 12.72 billion by 2031
Mordor Intelligence reports the global antibiotic resistance market is estimated at USD 9.78 billion in 2026 and projected to reach USD 12.72 billion by 2031, registering a CAGR of 5.40%. Growth is driven by rising drug-resistant infections, increased investments in research, and advancements in diagnostic tools and novel therapies. Major pharmaceutical companies including Pfizer, Merck, and GlaxoSmithKline are expanding antimicrobial pipelines. The report highlights regional dynamics across North America, Europe, and Asia-Pacific.
AI-powered CRISPR-on-a-chip technology enables portable high-sensitivity diagnostics
Researchers are developing CRISPR-on-a-chip platforms combining nanoscale engineering and microfluidics for portable diagnostics. These devices, potentially integrated with smartphones, aim to detect pathogens, genetic mutations, and cancer biomarkers without a laboratory. Technologies include fluorescent reporting systems and graphene-based sensors (gFET). While fluorescent systems offer multiplexing, gFET provides extreme single-molecule sensitivity for early cancer detection. Both approaches are in early development, with potential hybrid systems expected to balance speed, cost, and sensitivity for future point-of-care use.
Eli Lilly expands dealmaking while Regeneron secures historic gene therapy approval
Eli Lilly announced significant acquisitions including Ajax Therapeutics and Kelonia Therapeutics during its upcoming Q1 earnings discussion. Concurrently, Regeneron received FDA approval for Otarmeni, the first gene therapy targeting hearing loss. The FDA also requested the removal of Amgen's Tavneos due to trial data manipulation concerns and issued priority vouchers to psychedelic developers. Sanofi and Novartis are also defending patents for Dupixent and Lutathera respectively.
FTSE 100 pharma giants defy policy pressures with strong start
UK pharmaceutical companies, including AstraZeneca and GSK, began the year with stronger-than-expected earnings momentum despite global policy pressures. The sector demonstrated resilience through robust performance in oncology, vaccines, and specialty medicines. While US pricing policies introduce long-term uncertainty regarding revenue models and innovation incentives, strong pipelines and defensive market characteristics support continued growth. The outlook remains cautiously optimistic as firms balance innovation with regulatory challenges.
Study finds imperfect diagnostic tests can match perfect tests for measles outbreak detection under specific conditions
Researchers simulated measles outbreak detection using stochastic SEIR models to evaluate the impact of imperfect diagnostic tests against background noise. Results indicate that with static noise, rapid diagnostic tests (RDTs) achieved 90% accuracy comparable to perfect tests. However, with dynamical noise, perfect tests outperformed RDTs (approx 90% vs <= 80%), especially when noise magnitude was high. The study concludes that surveillance system performance is highly sensitive to noise structure and magnitude, suggesting RDTs are viable in low-noise contexts but may struggle in high-dynamical noise environments.
Chiesi acquires Kalvista for $1.9bn to add on-demand HAE drug
Chiesi Group has agreed to acquire Kalvista Pharmaceuticals Inc. for approximately $1.9 billion, valuing the company at $27 per share. The deal includes Kalvista's recently approved hereditary angioedema (HAE) drug, Ekterly (sebetralstat), which is the only orally available on-demand treatment for the condition. This acquisition marks Chiesi's largest to date and expands its rare disease franchise.
EMA launches pilot programme for breakthrough medical devices in EU
The European Medicines Agency (EMA) has launched a pilot programme to test a new regulatory pathway for breakthrough medical devices within the European Union. The initiative aims to accelerate patient access to highly innovative technologies while maintaining rigorous safety standards. Manufacturers of class III and class IIb devices can now request priority scientific advice. This pilot builds on guidance published by the European Commission's Medical Device Coordination Group in December 2025 and aligns with the EU Biotech Act objectives. The programme is a first step towards the formal implementation of a framework included in the December 2025 proposal for revising the Medical Devices Regulation.